Composition for preventing or treating colon cancer containing daunorubicin or a pharmaceutically acceptable salt thereof as an active ingredient
Daunorubicin-based compositions target the Hedgehog pathway to inhibit colorectal cancer cell proliferation and enhance anticancer drug efficacy, offering a synergistic effect when used in combination with other drugs.
Patent Information
- Application Number
- KR1020230184740
- Authority / Receiving Office
- KR · KR
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2023-12-18
- Publication Date
- 2026-08-03
- Estimated Expiration
- 2043-12-18
AI Technical Summary
Current treatments for colorectal cancer are inadequate, and there is a need for compositions that can inhibit the Hedgehog signaling pathway to enhance the effectiveness of anticancer drugs.
A pharmaceutical composition comprising daunorubicin or its pharmaceutically acceptable salts is developed to inhibit GLI-dependent transcription and the Hedgehog pathway, thereby inhibiting cancer cell proliferation and inducing apoptosis, and can be administered alone or in combination with other anticancer drugs.
Daunorubicin effectively inhibits the Hedgehog pathway in colorectal cancer cells, inducing apoptosis and enhancing the efficacy of anticancer drugs, particularly in GLI1-overexpressing cells, demonstrating a synergistic effect when combined with commercially available anticancer agents.